Critical Survey: AB Corporate Bond ETF (NASDAQ:EYEG) versus Decoy Therapeutics (NASDAQ:DCOY)

AB Corporate Bond ETF (NASDAQ:EYEG) and Decoy Therapeutics (NASDAQ:DCOY) are both small-cap companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, analyst recommendations, profitability, dividends, earnings, risk and institutional ownership.

Analyst Recommendations

This is a breakdown of current ratings for AB Corporate Bond ETF and Decoy Therapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AB Corporate Bond ETF	0	0	0	0	0.00
Decoy Therapeutics	1	0	1	0	2.00

Decoy Therapeutics has a consensus price target of $30.00, indicating a potential upside of 591.24%. Given Decoy Therapeutics’ stronger consensus rating and higher probable upside, analysts plainly believe Decoy Therapeutics is more favorable than AB Corporate Bond ETF.

Risk & Volatility

AB Corporate Bond ETF has a beta of 0.18, meaning that its stock price is 82% less volatile than the S&P 500. Comparatively, Decoy Therapeutics has a beta of 0.64, meaning that its stock price is 36% less volatile than the S&P 500.

Profitability

This table compares AB Corporate Bond ETF and Decoy Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
AB Corporate Bond ETF	N/A	-104.96%	-60.03%
Decoy Therapeutics	N/A	-395.42%	-193.30%

Institutional and Insider Ownership

64.2% of AB Corporate Bond ETF shares are owned by institutional investors. Comparatively, 11.9% of Decoy Therapeutics shares are owned by institutional investors. 58.2% of AB Corporate Bond ETF shares are owned by company insiders. Comparatively, 1.7% of Decoy Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares AB Corporate Bond ETF and Decoy Therapeutics”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AB Corporate Bond ETF	$12,059.00	2,290.74	-$8.09 million	($1.68)	-20.55
Decoy Therapeutics	N/A	N/A	-$12.52 million	($106.90)	-0.04

AB Corporate Bond ETF has higher revenue and earnings than Decoy Therapeutics. AB Corporate Bond ETF is trading at a lower price-to-earnings ratio than Decoy Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

AB Corporate Bond ETF beats Decoy Therapeutics on 7 of the 12 factors compared between the two stocks.

About AB Corporate Bond ETF

EyeGate Pharmaceuticals, Inc. is a clinical stage specialty pharmaceutical company, which engages in the development and commercialization of products for treating diseases and disorders of the eye. Its pipeline includes MoxiGel and Ocular Bandage Gel. The company was founded in 1998 and is headquartered in Waltham, MA.

About Decoy Therapeutics

Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds; HLB Life Sciences to develop, produce, manufacture, use, and sell the drug in South Korea; and Cancer Prevention and Research Institute of Texas for product development activities, as well as a research partnership with the Cancer Epigenetics Institute at Fox Chase Cancer Center to identify new indications and biomarkers for SP-2577. The company is headquartered in Houston, Texas.